Is the Kiniksa Pharmaceuticals International (KNSA) investment thesis intact?

Yes. Readouts currently rates the Kiniksa Pharmaceuticals International Thesis Intact. ARCALYST guidance rises again; PASTORALE data expected in second half of 2027.

What is the next catalyst for Kiniksa Pharmaceuticals International (KNSA)?

The next dated event is Phase 1 start for KPL-1161, expected end of 2026, as stated by the company.

How long will Kiniksa Pharmaceuticals International's cash last?

Kiniksa Pharmaceuticals International has said its cash will fund operations for at least the next 12 months (guidance as of October 27, 2026). It reported $569 million in cash as of September 30, 2026.

KNSAKiniksa Pharmaceuticals International, plc

IntactLast material event Jul 28, 2026 · Updated Oct 27, 2026

ARCALYST guidance rises again; PASTORALE data expected in second half of 2027

Kiniksa Pharmaceuticals sells ARCALYST, an approved weekly injection for recurrent pericarditis, and is developing KPL-387, a once-monthly injection for the same disease.

Kiniksa's case rests on approved ARCALYST growth funding its next generation of pericarditis treatments. Third-quarter revenue reached $286.0 million; 2026 sales guidance is between $1.045 billion and $1.050 billion. Operating cash generation supports development, with annual cash-flow-positive guidance conditional on the current plan. Monthly KPL-387 is enrolling in pivotal PASTORALE, with data expected in the second half of 2027 and commercialization targeted for 2028/2029. Quarterly KPL-1161 remains preclinical, with Phase 1 initiation expected by end of 2026.

Thesis checklist

0 risks need attention

Select a row for evidence

What must be trueStateNext proof

ARCALYST sales keep growingSupportedFull-year sales delivery against raised guidance and further patient adoption.Next: Full-year sales delivery against raised guidance and further patient adoption.

Why it is in this state

The evidence, what would weaken it and the source filing

KPL-387 succeeds in PASTORALEAwaiting evidencePASTORALE recurrence and safety results, expected in the second half of 2027.Next: PASTORALE recurrence and safety results, expected in the second half of 2027.

Why it is in this state

The evidence, what would weaken it and the source filing

Kiniksa funds itself from salesSupportedAnnual operating cash generation while meeting manufacturing commitments and funding development.Next: Annual operating cash generation while meeting manufacturing commitments and funding development.

Why it is in this state

The evidence, what would weaken it and the source filing

Next decision point

Can monthly KPL-387 prevent recurrence in PASTORALE?

Tests: KPL-387 succeeds in PASTORALE

Data expected in the second half of 2027.

Does monthly KPL-387 delay adjudicated recurrence versus placebo with acceptable safety in PASTORALE?

Strong, inconclusive and weak outcomes

What to look for in the result and how each would move the checklist

Questions to investigate

History

Price and material events

Select an event marker to read the update below. Marker colors show Thesis status.

IntactCurrentClinical

+25.0%Jul 28, 2026

ARCALYST guidance rises again; PASTORALE data expected in second half of 2027

IntactCommercial

+23.5%Apr 28, 2026

KPL-387 Phase 2 data will test whether Kiniksa can build a second IL-1 franchise beyond its ARCALYST cash engine in recurrent pericarditis

About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.

Pipeline

IL-1-mediated disease

KPL-1161 · 1 upcoming

Phase 1 Study Initiation

end of 2026

Pericarditis

KPL-387 · 3 upcoming · 3 completed

Phase 3 DataPASTORALEPivotal

2H 2027

Phase 2 Study Initiation

TBD

Commercial Launch

2028/2029

Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.

Quick answers

Is the Kiniksa Pharmaceuticals International (KNSA) investment thesis intact?: Yes. Readouts currently rates the Kiniksa Pharmaceuticals International Thesis Intact. ARCALYST guidance rises again; PASTORALE data expected in second half of 2027.
What is the next catalyst for Kiniksa Pharmaceuticals International (KNSA)?: The next dated event is Phase 1 start for KPL-1161, expected end of 2026, as stated by the company.
How long will Kiniksa Pharmaceuticals International's cash last?: Kiniksa Pharmaceuticals International has said its cash will fund operations for at least the next 12 months (guidance as of October 27, 2026). It reported $569 million in cash as of September 30, 2026.

Disease areas: Obesity, diabetes and heart disease, Autoimmune and inflammatory diseases, Rare genetic and metabolic diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes

Competitive landscape

1 peers tracked

Financial snapshot

Dates and calculation details

Cash: Market-data provider estimate; measurement period unavailable.

Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.

Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.

Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.

Runway: No underlying guidance available.